NCT00579670 - Treatment of Schizophrenic Patients With Ziprasidone | Biotech Hunter

Enrollment

450

Participants

Timeline

Start Date

October 31, 2007

Primary Completion Date

April 30, 2009

Study Completion Date

April 30, 2009

Conditions

Schizophrenia

Interventions

DRUG

Ziprasidone

Ziprasidone 20mg, 40mg, 60mg, 80mg capsules, hard; Ziprasidone 10 mg/ml oral suspension Ziprasidone 20mg/ml powder and solvent for the reconstitution of solution for injection

Trial Locations (20)

12461

Pfizer Investigational Site, Athens

Pfizer Investigational Site, Chaïdári

Pfizer Investigational Site, Haidari

12462

Pfizer Investigational Site, Chaïdári

24100

Pfizer Investigational Site, Kalamata

26000

Pfizer Investigational Site, Pátrai

26001

Pfizer Investigational Site, Pátrai

35100

Pfizer Investigational Site, Lamia

38222

Pfizer Investigational Site, Volos

49100

Pfizer Investigational Site, Corfu

50100

Pfizer Investigational Site, Kozani

56430

Pfizer Investigational Site, Thessaloniki

57010

Pfizer Investigational Site, Thessaloniki

58100

Pfizer Investigational Site, Giannitsá

60100

Pfizer Investigational Site, Katerini

124 61

Pfizer Investigational Site, Chaïdári

731-00

Pfizer Investigational Site, Crete

Unknown

Pfizer Investigational Site, Kozani

Pfizer Investigational Site, Larissa

564-29

Pfizer Investigational Site, Thessaloniki

All Listed Sponsors

lead

Pfizer's Upjohn has merged with Mylan to form Viatris Inc.

INDUSTRY